首页> 外文期刊>Journal of Drug Delivery and Therapeutics >FORMULATION OF AN INSITU FORMING INJECTABLE SUSTAINED RELEASE SPONGE OF GRANISETRON HYDROCHLORIDE
【24h】

FORMULATION OF AN INSITU FORMING INJECTABLE SUSTAINED RELEASE SPONGE OF GRANISETRON HYDROCHLORIDE

机译:格拉司琼盐酸盐的原位形成的可注射持续释出海绵的配方

获取原文
           

摘要

The overall aim of this work was to develop sustained release parenteral drug delivery system involving formation of an insitu sponge of an anti-emetic drug typically co-administered inchemotherapy induced nausea and vomiting. The study involved formulation of the drug Granisetron Hydrochloride in a sponge forming gelatin matrix as a dry powder for reconstitution into a suspension to be injected into the body forming a sponge insitu intended to release the drug over a period of 5 days. The formulation was prepared by the method cryogelation and optimised using gelatin5% as a sponge forming polymer, crosslinking agent glutaraldehyde 0.3% , sustained release retardant Hydroxypropylmethyl cellulose K100M 1% (HPMC K100M) and suspending agent sodium carboxymethylcellulose 1% (NaCMC) to form a solution intended to be administered subcutaneously. The formulation was evaluated for all prerequisites of parenteral and other parameters of gelatin matrix like swelling index, surface scanning microscopy .for injectable suspension, sedimentation study, particle size,zeta measurement, invitro drug release, and stability studies. The formulation was found tosterile, isotonic, having swelling index 88% and SEM 100-120 μm,particle size 0.765μm.with zeta potential-14.2 mV, swelling time was 10 min. The in vitro drug release was found to be over 93.20% in Simulated Body fluid pH 7.4 at 37°C over a prolong period of 5days The formulation was physically and chemically stable at accelerated conditions for period of 1 month.
机译:这项工作的总体目标是开发持续释放的肠胃外药物输送系统,该系统涉及形成通常联合镇痛疗法引起的恶心和呕吐的止吐药物的原位海绵。该研究涉及在海绵状明胶基质中将药物盐酸盐酸格拉司琼配制成干粉,以复配成悬浮液,再注入体内形成海绵状原位,以在5天内释放出药物。通过冷冻凝胶法制备制剂,并使用明胶5%作为形成海绵的聚合物,交联剂戊二醛0.3%,缓释阻滞剂羟丙基甲基纤维素K100M(HPMC K100M)和悬浮剂羧甲基纤维素钠1%(NaCMC)进行优化。旨在皮下给药的溶液。对制剂的肠胃外条件和明胶基质的其他参数(如溶胀指数,表面扫描显微镜,注射悬浮液,沉降研究,粒度,ζ测量,体外药物释放和稳定性研究)的所有先决条件进行了评估。发现该制剂是无菌的,等渗的,溶胀指数为88%,SEM为100-120μm,粒径为0.765μm,ζ电位为14.2mV,溶胀时间为10分钟。发现在37℃下在5天的延长时间内在pH 7.4的模拟体液中体外药物释放超过93.20%。该制剂在加速条件下在物理和化学上稳定1个月。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号